← Back

Wire · opportunities

BCAL widens breast cancer research beyond lipids as its science goes through peer review

Published

17 November 2026

Topic

opportunities

◆ Sectors

Health

◆ Geography

Australia

◆ Source

Read at biotechdispatch.com.au →

◆ Verified

Fusion42 · 17 November 2026 · Fusion42 review

BCAL Diagnostics has expanded its breast cancer research from lipidomics to include multiomic assays like epigenomic biomarkers, supported by recent peer-reviewed publications and ethics approval. This strengthens its diagnostic platform and clinical application of its blood test BREASTESTplus for early breast cancer detection.

This Wire brief sits within Fusion42's coverage of Health.

◆ ◆ The Wire takeaway

You can now push beyond lipid markers in breast cancer testing by incorporating multiomic signals like epigenomics, opening clinical test innovation paths in Australia. This is your moment to engage with more comprehensive biomarker platforms for earlier and more reliable breast cancer detection.

◆ Coverage

1 source · 17 Nov 2026

◆ Related on Wire

◆ Topics

Healthbreast-cancermultiomic-assayslipidomicsdiagnosticspeer-review